The effects of tumour-promoting phorbol esters on the receptor-mediated endocytosis of insulin were investigated in the human hepatoma cell line HepG2. Treatment of these cells with the biologically active phorbol 12-O-tetradecanoylphorbol 13-acetate (TPA), but not with the non-tumour-promoting analogue 4a-phorbol 12,13-didecanoate, resulted in dramatic morphological changes, which were accompanied by a 1.5-2.5-fold increase in specific 1251-insulin association with the cells at 37 'C. This increase in insulin binding was not observed when the binding reaction was performed at 4 'C. The potentiation of 1251-insulin association with TPA-treated cells at 37 'C could be completely accounted for by an increase in the intracellular pool of internalized insulin; there was no concomitant increase in cell-surface insulin binding. Dissociation studies showed that the enhanced internalization of insulin by cells after treatment with TPA resulted from a decrease in the rate of intracellular processing of the insulin after receptor-mediated endocytosis. The phorbol-ester-induced enhancement ofinternalized insulin in HepG2 cells was additive with the potentiation of endocytosed insulin induced by both the lysosomotropic reagent chloroquine and the ionophore monensin; this indicates that TPA affects the intracellular processing of the insulin receptor at a point other than those disrupted by either of these two reagents. The potentiation of insulin receptor internalization by tumour-promoting phorbol esters could be completely mimicked by treatment with phospholipase C, but not with phospholipase A, and partially mimicked by treatment with the synthetic diacylglycerol 1-oleoyl-2-acetylglycerol. By these criteria, the effects of phorbol esters on the insulin receptor in HepG2 cells appear to be mediated through protein kinase C. These results support the concept that the activation of protein kinase C by treatment with phorbol esters causes a perturbation of the insulinreceptor-mediated endocytotic pathway in HepG2 cells, reflected in a long-term decreased rate ofdissociation of internalized insulin by the phorbol-ester-treated cells.
INTRODUCTION
Tumour-promoting phorbol esters have been shown to induce a multitude of effects, both morphological and biochemical, when added to mammalian cell lines (for reviews, see Diamond et al., 1978; Blumberg, 1980) . Although the direct mechanism by which phorbol esters induce cell transformation remains unclear, it is suggested that the biologically potent promoter 12-0-tetradecanoylphorbol 13-acetate (TPA) mediates intracellular events which mimic those of endogenous polypeptide growth factors. There is evidence that these effects are due, at least in part, to the substitution of TPA for the putative intracellular mediator, diacylglycerol. In intact cells, diacylglycerol is produced as a result of phosphatidylinositol turnover, a metabolic pathway which has been implicated in the actions of several hormones (Michell, 1975; Berridge & Irvine, 1984) . Work by Nishizuka and others suggest that a Ca2+, diacylglycerol-and phospholipid-dependent protein kinase is responsible for the transduction of the effects of both TPA and diacylglycerol, via an enzymic activation of the protein kinase, termed protein kinase C, and subsequent phosphorylation of cellular proteins (Kishimoto et al., 1980; Castagna et al., 1982; Lapetina et al., 1985) . Other studies have also shown that the receptor for TPA co-purifies with protein kinase C, further reinforcing the hypothesis that this widely distributed enzyme plays a role in the intracellular mediation of tumour promotion or cell transformation (Niedel et al., 1983) .
A number of cellular proteins have been shown to undergo phosphorylation upon exposure of intact cells to TPA. Although the biological function of several of these proteins remains to be identified (Sano et al., 1983; Seiss et al., 1983; Lapetina et al., 1985) , the TPA-promoted phosphorylations which have been shown to occur at the receptors for epidermal growth factor (Cochet et al., 1984; Iwashita & Fox, 1984; Friedman et al., 1984) , insulin-like growth factor (Jacobs et al., 1983) , transferrin (May et al., 1984) , catecholamines (Kelleher et al., 1984; Sibley et al., 1984) and insulin (Jacobs et al., 1983; Takayama et al., 1984) are frequently accompanied by changes in receptor functionality or subcellular distribution, implicating protein kinase C in the modification of receptor-mediated actions.
Studies aimed at determining the sites of action of the protein-kinase-C-mediated phosphorylation of the epidermal-growth-factor receptor and the insulin receptor have shown a specific increase in the phosphorylation of serine and threonine residues (Jacobs et al., 1983; Cochet et al., 1984; Iwashita & Fox, 1984; Friedman et al., 1984) . In many cases, this increased receptor phosphorylation has been shown to be accompanied by decreases in either high-affinity hormone binding or receptor-mediated physiological function; these effects appear to vary significantly from one cell line to the next. These changes may be due, in part, to the attenuation of the receptor-specific tyrosine kinase activity, which has been shown to be associated with both of these receptors; however, a direct correlation between both effects has yet to be shown.
In the present paper, we demonstrate that TPA treatment of the human hepatoma cell line HepG2 results in an increase in specific 1251-insulin association with intact cells at physiological temperatures. This increase in cell-associated hormone arises not from a change in either the number or the affinity ofcell-surface insulin receptors, but rather from an increase in the pool of internalized insulin in the TPA-treated cells, mediated via a decrease in the rate of intracellular processing of insulin. Furthermore, it is possible to mimic the effects of TPA in these cells through the addition of the diacylglycerol derivative 1 -oleoyl-2-acetylglycerol (OAG) and through the production of diacylglycerol by the addition of exogenous phospholipase C, demonstrating that this perturbation ofthe pathway ofinsulin-receptor-mediated endocytosis in HepG2 cells is mediated through protein kinase C.
EXPERIMENTAL Materials
1251-insulin (2200 Ci/mmol) was obtained from New England Nuclear. TPA, 4a-phorbol 12,13-didecanoate, cycloheximide, chloroquine, phospholipase A and bovine serum albumin were from Sigma. Insulin was obtained from Elanco. Tissue-culture media and supplies were from Gibco. Hepes, monensin and phospholipase C were purchased from Calbiochem, and trypsin was from Worthington.
HepG2 cells were provided by Dr B. B. Knowles, Wistar Institute, Philadelphia (Knowles et al., 1980) . OAG was a gift from Dr. Y. Nishizuka, Kobe University, Japan (Kaibuchi et al., 1983) . Cell culture HepG2 cells were grown as monolayer cultures to a final density of 106 cells/well in 24-well culture dishes in Modified Eagle's Medium with Earle's balanced salt solution (MEM; Gibco), supplemented with 1 mm non-essential amino acids, 10% (v/v) fetal-calf serum, 2 mM-glutamine, 0.1 mg of streptomycin/ml and 100 units of penicillin/ml. A humidified atmosphere of C02/air (2:23) was maintained for cell growth at 37 'C. Cells were passaged at 96 h after being dispersed with 0.250 trypsin/ I mM-EDTA. Confluent monolayers were utilized in all experiments. Non-specific binding, determined with the addition of 10 JaM unlabelled insulin, was less than 5%, of the total bound. After binding, cells were quickly washed three times in cold Hanks buffer (Hanks balanced salt solution containing 20 JM-Hepes and 0.1 % albumin, pH 7.4), removed from the dish by treatment with 0.5 mg of trypsin/ml for 30 min at 250 C, or with 0.1 M-NaOH, and counted for radioactivity in a Beckman gamma counter. For Scatchard analysis, binding was performed at 4°C overnight and data were analysed by the method of Munsen & Rodbard (1980) , by using the LIGAND computer program.
For internalization of the receptor, cell monolayers were incubated with '251-insulin at 37°C for various times as indicated in the Figure legends . At the end of the incubation, cells were washed three times with cold Hanks bufferand thecell-surface receptor bindingwas inactivated by trypsin (0.5 mg/ml for 30 min at 25°C). The cells were then removed from the plate, washed twice with cold Hanks buffer, and the 125I present in the cell pellet was counted to quantify internalized receptor. These trypsintreatment conditions were adjusted such that 95% of the cell-surface-bound insulin was removed when the binding was performed at 4°C to inhibit internalization. Total cellular receptor was measured in parallel plates by counting cells for radioactivity directly after removal from the plate, with no further washing. In experiments designed to measure the effects of various reagents on receptor binding and internalization, cells were first incubated with the reagent as described in the Figure  legends 1251-insulin was bound to HepG2 monolayers at 370C for 30 min as described above. After the removal of free 1251-insulin, 0.25 ml of fresh MEM/Hepes buffer was added. At various times, samples of the supernatant were removed from the monolayer and the dissociated 1251 present in the supernatant was measured. The percentage of radioactivity present as protein was determined by precipitation with 10% (v/v) trichloroacetic acid with 1 % albumin (Fraction V) as the carrier. The amount of cell-associated radioactivity remaining at various times was determined by quickly washing the monolayers with cold Hanks buffer before removing them from the plate with 0.1 M-NaOH and counting for radioactivity. Phorbol ester treatment TPA and 4x-phorbol 12,13-didecanoate were each dissolved in ethanol and stored in the dark at -20°C. HepG2 monolayers were washed twice in MEM/20 mMHepes/0. 1 % albumin, pH 7.4, before the addition of the phorbol ester, diluted in this same buffer. All incubations with TPA were performed for 2 h at 37°C, unless otherwise noted in Figure legends . At the end of the incubation time, the cells were washed three times in cold MEM buffer before 1251-insulin binding and internalization were measured as described above. The ethanol added with the TPA had no effect on the experimental results. The results presented here were also independent of whether or not the excess TPA was removed by washing before 1251-insulin binding to the cells.
Phospholipase treatment
Washed HepG2 monolayers were incubated in MEM/ Hepes buffer for 30 min at 37°C with either phospholipase C or phospholipase A at a final concentration of 10 munits/ml. After this time, 1251-insulin was added to the cells, and binding and internalization were measured for an additional 30 min at 37°C as described above. Treatment with OAG OAG was stored as a chloroform solution of 100 mg/ml at -20 'C. For use with HepG2 cells, the chloroform was evaporated from a sample ofOAG under a stream ofNa before the addition ofMEM/Hepes buffer. The mixture was sonicated on ice to the point of minimum turbidity (approx. 10 min). Cells were preincubated for various times with OAG concentrations of 0.01-0.2 mg/ml before the addition of 1251-insulin for cell-binding measurements. Photography HepG2 cells were grown in 60 mm culture dishes to a stage ofearly confluence. Incubations with phorbol esters were performed as described in Fig. 1 legend in 2 ml of MEM/Hepes buffer. Cells were photographed from a Zeiss microscope equipped with a Nikon camera and Kodak PX-135 film.
RESULTS
Treatment of various cells with tumour-promoting phorbol esters results in characteristic morphological changes, primarily reflecting changes in the cell membrane compartments (Diamond et al., 1978; Blumberg, 1980 Blumberg, , 1981 . As shown in Fig. 1 , the treatment of the HepG2 hepatoma cell line with TPA, a tumour-promoting phorbol ester, resulted in dramatic changes in the cell morphology. The TPA-treated cells in monolayer culture maintained a rounder shape, with membranes that were visually more sharply defined by phase-contrast light microscopy than the relatively flat, spread-out, control cells. These morphological changes were dependent on the time of incubation with TPA and on TPA concentration, with the half-maximal effects of 1 ,#M-TPA observed at approx. 1 h. In contrast, treatment of these cells with the non-tumour-promoting phorbol esters 4ac-phorbol didecanoate and TPA 4-0-methyl ester resulted in no changes in the cell morphology, as assessed by phase-contrast light microscopy. These dose-dependent TPA-induced changes in the morphology of HepG2 cells were accompanied by an increase in specific insulin association with the cell monolayer at 37°C, as shown in Fig. 2 association to 1.9-fold (P < 0.01) occurred in response to preincubation with 1 /sM-TPA, with an ED50 of approx.
0.1 /bM. This dose-response of the increase in 1251I-insulin binding to HepG2 cells as a function of TPA concentration paralleled that of the TPA-induced morphological changes shown in Fig. 1 . The increase in 1251-insulin association was not accompanied by any increase in total cellular protein (results not shown). Parallel incubations with the biologically inactive phorbol ester 4a-phorbol didecanoate at concentrations up to 10 /M resulted in no change in the subsequent association of 1251-insulin with HepG2 cells (Fig. 2) . The enhancement of specific 125I-insulin association with HepG2 cells at 37 "C by preincubation with TPA was not reversed by the removal of excess TPA from the monolayer. This is shown in Fig. 3 , where cells were preincubated with 1 ,sM-TPA for 2 h before excess TPA was washed away and 1251-insulin was bound to the cells at 37 'C. In control cells or in cells treated with the biologically inactive 4a-phorbol didecanoate, the binding of 125I-insulin to the cells increased rapidly for the first 15 min, after which it gradually fell to 63% of maximal binding after 8 h with 125I-insulin. In TPA-treated cells, the amount of 125I-insulin binding also rose to a maximal value within 15 min, but then remained at a plateau for the next several hours; the-maximal binding was higher and the decrease in bound 125I-insulin with time was slower in TPA-treated cells than in controls. Both of these aspects of 125I-insulin association with TPA-treated cells contributed to the enhancement of binding observed under these conditions.
Like the morphological changes depicted in Fig. 1 , the TPA-induced increase in -1251-insulin association with HepG2 monolayers was dependent on the time of preincubation of the cells with TPA at 37 'C, as shown in Fig. 4(a) . The potentiation of specific cell-associated 1251-insulin induced by 1 1sM-TPA continued to increase for approx. 2 h. Thereafter, the amount of 125I-insulin associated with the cell monolayer remained constant, with a maximal increase of2.2-fold over control cells. The half-time of this increase was approx. 60 min with 1 /sM-TPA. Comparable incubations with the biologically inactive 4a-phorbol didecanoate at 1 /tM had no effect on the binding of 1251-insulin to HepG2 cells throughout the 4 h period (Fig. 4a) .
Under the conditions in which the binding of1251-insulin to these HepG2 cells was measured (i.e. at 37°C), the insulin-receptor complex would rapidly be internalized in response to insulin binding (ti = 2 min; Strader et al., 1985) , and the receptor recycled to the cell surface as a function of time. It was therefore decided to determine whether the TPA-induced increase in 1251-insulin association with the cells reflected an increase in the amount of cell-surface-bound insulin, an increase in internalized insulin, or a combination of the two possibilities. To approach this question, 1251-insulin was bound to TPA-treated cells and the cell-surface receptors were Fig. 4(b) . Preincubation of the cells with 1 ,sM-TPA caused a time-dependent increase in internalized 125I-insulin; the percentage of cellassociated '251-insulin that was internalized by the cell within 4 h at 37 "C rose from 50% in control cells to a maximum of 72% after 4 h of preincubation with TPA, a 2.4-fold enhancement of the internal pool of insulin. Cells treated-with the non-tumour-promoting 4x-phorbol didecanoate, on the other hand, showed no such increase in the binding or internalization of 125I-insulin throughout the 4 h period. When the relative contributions of cell-surface-bound and internalized 1251-insulin to the increase in cell-associated insulin were assessed, it was determined that the increase in internalized 1251-insulin accounted for all of the observed increase in 1251-insulin binding to the cell. Thus the increase in 125I-insulin binding to HepG2 cells promoted by the phorbol ester TPA resulted entirely from an increase in the intracellular pool of 1251-insulin, with no increase in the binding of 125I-insulin to the cell surface receptors.
The fact that the increase in the binding of 1251-insulin to HepG2 cells after preincubation with TPA did not result from an increase in cell-surface insulin receptors is also illustrated by a comparison of insulin binding to TPA-treated cells at 4 "C and at 37 "C, as shown in Fig.  5 . In these experiments, all cells were treated with 1 /tM-phorbol ester for 2 h at 37°C before the cells were washed and insulin was bound at either 4" (Fig. 5a) or 37 "C (Fig. Sb) . Examination of the data in Fig. 5(a) shows that there was no change in the binding of 1251-insulin at 4 "C to cells that had been pretreated with either the tumour promoter TPA or the biologically inactive 4a-phorbol didecanoate at 37 'C. Scatchard analysis of the high-affinity insulin binding to these cells at 4°C revealed a KD of 5.5 (+ 1.6) x 10-10 M for control cells and 5.0 (+0.8) x 10-10 M for TPA-treated cells (P > 0.05, n = 8). The receptor concentration for control cells was 2.3 (±0.7) x 10-10 M, and thatofthe TPA-treated cells was 1.9 (±0.3) x 10-10 M (P > 0.05, n = 4).
In contrast, insulin competition curves generated at 37 'C on identically treated cells showed an enhancement of specific 1251-insulin association with the cells after pretreatment with TPA, but no change after pretreatment with 4a-phorbol didecanoate (Fig. 5b) Dissociation of cell-associated 125I-insulin is a much slower process, however (ti = 20 min), and dramatic differences in this parameter between control cells and TPA-treated cells were detected, as shown in Fig. 6 . In this experiment, cells were exposed to 1 1sM-TPA and 125I-insulin was bound at 37 'C. After washing to remove unbound insulin, the cells were returned at 37 "C to permit dissociation of prebound 1251I-insulin. After an initial lag period of 5 min, the rate of dissociation of 125I-insulin from control cells, or from cells treated with 4a-phorbol didecanoate, was 2.3 times faster than that from cells treated with TPA. This faster rate of dissociation continued for approx. 45 minutes, after which time the release of radioactivity from both treated and control cells reached a plateau. It is noteworthy that, at all time points, the fraction of the radioactivity released from the cell which was present in the form of protein, as judged by precipitation with trichloroacetic acid, was identical in control and TPA-treated cells. After 5 min of dissociation, 56+ 1 % of the 125I released from both control and TPA-treated cells could be precipitated by trichloroacetic acid, whereas after 1 h only 22+1 % of the 1251 dissociated from both sets of cells was in the form of protein.
Further evidence for the effects of TPA on the intracellular processing of the insulin-receptor complex came from experiments investigating the effects of chloroquine and monensin on 125I-insulin binding and internalization by HepG2 cells. The lysosomotropic reagent chloroquine has been shown to enhance the size of the pool of internal insulin receptors (Marshall et al., 1981; Green & Olefsky, 1982) . This reagent, which acts by raising the pH of lysosomes and other intracellular organelles, inhibits the dissociation ofthe receptor-insulin complex, thus inhibiting the recycling of receptors and enlarging the intracellular pool of internalized insulin.
The ionophore monensin has also been shown to inhibit receptor recycling in various systems (Basu et al., 1981) .
As shown in Fig. 7(a) , preincubation of either 0.1 mmchloroquine or 10 /SM-monensin with HepG2 cells before treatment with 4a-phorbol didecanoate resulted in a 2.2-fold increase in subsequent125I-insulin binding to the cells in 1 h at 37 'C. Treatment of cells with TPA alone caused a 1.8-fold increase in 125I-insulin bound, as shown in Fig. 7(b) . When cells were preincubated with either 0.1 mM-chloroquine or 10 /sM-monensin before treatment with TPA, there was a further enhancement of 1251-insulin binding, to 2.7-fold that of the untreated control, or 1. (Davis et a!., 1985) .
Phospholipase C has also been shown to stimulate protein kinase C by raising intracellular concentrations of diacylglycerol (Allan et al., 1978) . When HepG2 cells were incubated with phospholipase C, there was a dose-dependentincreasein subsequent 1251-insulin binding to the cells, with the maximal effect being observed with 10 munits of phospholipase C/ml. As shown in Fig. 8(a) activate protein kinase C. Fig. 8(b) shows the effects of phospholipase C on the subsequent internalization of '251-insulin by HepG2 cells at 37°. Again, 10 munits of phospholipase C/ml mimicked the effects of TPA in enhancing this parameter, whereas phospholipase A was without effect. It is noteworthy that the effects of maximally stimulating concentrations of phospholipase C and TPA were not additive, indicating that they were acting through the same pathway (results not shown). Thus the effects of TPA on the receptor-mediated internalization of insulin by HepG2 cells appear to be mediated through protein kinase C.
DISCUSSION
Treatment of HepG2 hepatoma cell monolayers with the tumour-promoting phorbol ester TPA resulted in dramatic morphological changes, visible at the lightmicroscopic level. These morphological changes correlated in a time-and dose-dependent fashion with an enhancement of the association of 1251-insulin with these cells at 37 'C. The TPA-promoted potentiation of insulin binding to the HepG2 cells resulted solely from an increase in internalized insulin, and not from a change in cell-surface receptor number, as reflected both in its temperature-dependence and in its resistance to degradation by trypsin. The additivity of the effects of phorbol esters with those of chloroquine and monensin provides further evidence that the potentiation of insulin binding by TPA results from a change in the receptor-mediated endocytotic pathway, rather than from a change in insulin receptor numbers.
The enhancement of the pool of internalized insulin observed in TPA-treated HepG2 cells resulted from a decrease in the rate of intracellular processing of the insulin. This was reflected in a decrease in the rate of dissociation of prebound insulin from cells which had been incubated with TPA, but not from cells incubated with the non-tumour-promoting 4a-phorbol didecanoate. Dissociation of prebound '251-insulin from HepG2 cells at 37°C presumably could reflect two major components: a direct dissociation of 125I-insulin from cell-surface receptors, or a dissociation via the endocytotic pathway, whereby the insulin-receptor complex is internalized and the two components are separated in an intracellular compartment before the 1251-insulin is released into the medium and the receptors recycled to the cell surface. In HepG2 cells, as in many cell types, the former pathway takes place very slowly, the long incubation times and more acidic conditions being required for the dissociation of the cell-surface insulin-receptor complex to occur; dissociation by this pathway is negligible over a period of 2 h at pH 7.4 (Strader et al., 1985) . Therefore the decreased rate of dissociation of the cell-associated '251-insulin in TPA-treated cells must reflect an effect of the phorbol ester on the release ofinternalized 1251-insulin from the cell.
Phorbol esters have been demonstrated to have a variety of effects on various hormone receptors in several different cell types. Grunberger & Gorden (1982) have reported that treatment of human U-937 macrophages or IM-9 lymphocytes with TPA decreased specific insulin binding at both 150 and 37°C, while having no effect on insulin binding to cultured human fibroblasts. Thomopoulos et al. (1982) also reported a decrease in insulin binding at 15°C to both U-937 cells and to the human leukaemic cell line HL-60, although with differential sensitivities. On the other hand, Takayama et al. (1984) have reported that insulin binding at 15°C to rat Fao hepatoma cells was unchanged by prior exposure of the cells to TPA. Since this binding was done at a non-permissive temperature for receptor internalization (15°C), it is not known whether the TPA-induced increase in internalized insulin that we report here for the human HepG2 hepatoma cell at 37°C would also be present in the rat Fao hepatoma cell at the higher temperature. However, it is clear that the HepG2 cell, the rat Fao hepatoma cell and the human fibroblasts did not show the TPA-induced loss of insulin binding observed in both the U-937 macrophages and IM-9 lymphocytes. Thus the effects of phorbol esters on receptor-mediated insulin binding vary from one cell type to another. The work presented here is the first report of an effect of phorbol esters on insulin-receptor endocytosis; the universality of this effect remains to be explored.
